

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Bisgaard-Frantzen et al. Serial No.: To be assigned

Confirmation No: To be assigned

Group Art Unit: To be assigned

Filed: July 10, 2001

Examiner: To be assigned

For: Amylase Variants

PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, DC 20231

Sir:

Before the above-captioned application is taken up for examination, entry of the following amendment is respectfully requested:

IN THE SPECIFICATION:

At page 1, after the title, insert

--CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application no. 09/354,191, filed on July 15, 1999, which is a continuation of U.S. patent no. 6,093,562, filed on February 13, 1996, which is a continuation of application serial no. PCT/DK96/00056, filed on February 5, 1996, which claims priority under 35 U.S.C. 119 of Danish application serial nos. 0126/95, filed on February 3, 1995, 0336/95, filed on March 29, 1995, 1097/95, filed on September 29, 1995, and 1121/95, filed on October 6, 1995, the contents of which are fully incorporated herein by reference.--


REMARKS

This amendment is submitted to incorporate a cross-reference to related applications.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

Date: July 10, 2001



Jason I. Garbell, Reg. No. 44,116
Novozymes North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123

100120 88720650